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mucosal adjuvants when co-presented on whole
inactivated influenza vaccines
Tila Khan1, Connie L Heffron1, Kevin P High2 and Paul C Roberts1*Abstract
Background: Potent and safe adjuvants are needed to improve the efficacy of parenteral and mucosal vaccines.
Cytokines, chemokines and growth factors have all proven to be effective immunomodulatory adjuvants when
administered with a variety of antigens. We have previously evaluated the efficacy of membrane-anchored
interleukins (IL) such as IL-2 and IL-4 co-presented as Cytokine-bearing Influenza Vaccines (CYT-IVACs) using a mouse
model of influenza challenge.
Findings: Here, we describe studies evaluating the parenteral and mucosal adjuvanticity of membrane-bound IL-12
and IL-23 CYT-IVACs in young adult mice. Mucosal immunization using IL-12 and IL-23 bearing whole influenza virus
vaccine (WIV) was more effective at eliciting virus-specific nasal IgA and reducing viral lung burden following
challenge compared to control WIV vaccinated animals. Both IL-12 and IL-23 bearing WIV elicited the highest
anti-viral IgA levels in serum and nasal washes.
Conclusions: This study highlights for the first time the mucosal adjuvant potential of IL-12 and IL-23 CYT-IVAC
formulations in eliciting mucosal immune responses and reducing viral lung burden. The co-presentation of
immunomodulators in direct context with viral antigen in whole inactivated viral vaccines may provide a means to
significantly lower the dose of vaccine required for protection.
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Introduction
The use of novel adjuvants, non-replicating virus-like
particles (VLP), whole inactivated influenza vaccines
(WIV), universal vaccines, and others are potential ap-
proaches to address current influenza vaccine challenges
[1,2]. Interestingly, in mice WIV have been shown to be
more immunogenic and induce superior mucosal IgA re-
sponses when administered intranasally (I.N.) compared
to split vaccines [3]. Intranasal administration of WIV can
lead to B cell dependent hetero-subtypic immunity that is
associated with elevated lung and serum sIgA and IgG
levels [4]. The use of novel adjuvants in combination with
WIV may serve to modulate and enhance both mucosal
and systemic immune responses with the potential benefit* Correspondence: pcroberts@vt.edu
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unless otherwise stated.of antigen sparing and costs associated with vaccine
production [5]. Cytokines have great potential to serve
as potent and specific adjuvants due to their diverse role
in immune responses [6,7]. They are actively being eval-
uated for use as adjuvants for intranasal vaccine formu-
lations [8] and have been used extensively as soluble
adjuvants co-administered with numerous vaccines [9,10],
or in a fused or linked form directly with antigen [7,11].
The superior immunogenicity of WIV as compared to split
or subunit influenza vaccines [12,13] encouraged us to
utilize WIV bearing cytokines as a more immunogenic
vaccine formulation.
Previous studies in our laboratory have evaluated the
adjuvant potential of membrane-anchored IL-2, IL-4 and
GM-CSF directly incorporated on inactivated influenza
virus particles in mice and chickens [14,15]. Cytokine
bearing Influenza Vaccine (CYT-IVAC) formulations are
derived from mammalian cell culture propagation tech-
niques. Here, influenza A virions are harvested fromd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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membrane-bound cytokines at their cell surfaces. As the
virus buds and is released they recognize and incorporate
the membrane-bound cytokine into the virion envelope.
In the present study we expanded our panel of immuno-
modulators to include IL-12 and IL-23 and evaluated their
immunogenicity and protective efficacy by different routes
of immunization in young adult mice. IL-12 is a Th1 po-
larizing cytokine that promotes the differentiation of naïve
CD4 + T helper cells towards a Th1 phenotype and stimu-
lates both NK cells and T cells to secrete the immuno-
modulatory cytokine, IFNγ [16,17]. Co-administration of
IL-12 during intranasal vaccination has proven to be
efficacious in stimulating enhanced immune responses
to pneumococcal [18] and HIV antigens [19] as well as
the induction of systemic and mucosal CTL responses
[20]. Recently, we demonstrated that both IL-2 and IL-12
can serve as immunopotentiating agents in influenza vac-
cines tailored for the elderly [21]. Here, we expanded upon
those observations and evaluated whether IL-12 and IL-23
in a membrane-bound formulation would serve as muco-
sal adjuvants for influenza WIV in young adult mice.
Methods
The cDNA encoding for mouse derived immunomod-
ulators IL-12 and IL-23 was fused inframe to the
membrane anchoring regions of the hemagglutinin (HA)
of A/WSN/33 influenza virus as previously described
[15,21]. The mIL-12 gene derived from pORF-mIL-12
(p35:p40) plasmid (InvivoGen) and the mIL-23 (p19:
p40) gene construct synthesized in vitro (GenScript®),
both encode for a single chain open reading frame in which
both subunits are linked by a hydrophobic linker molecule
(see Additional file 1: Figure S1). Cytokine gene amplicons
were further subcloned into the pcDNA3.1 ~ HA1513
vector using restriction endonuclease sites HindIII and
BamHI. Madin-Darby canine kidney cells (MDCK) con-
stitutively expressing membrane-bound IL12/HA and
IL23/HA were established and surface expression of mem-
brane bound cytokines was validated by indirect immuno-
fluorescence microscopy as described previously [15,21].
Double gradient purified whole inactivated influenza
vaccines (WIV) were produced from influenza A/PR/8/34
(H1N1) virus infected MDCK producer cell lines as de-
scribed previously and incorporation of membrane-bound
cytokines was further validated by western blot analysis of
whole viral lysates [15,21]. All animal experiments were
performed based on the guidelines of NIH and approval of
Institutional Animal Care and Use Committee (IACUC)
of Virginia Polytechnic Institute and State University.
8–10 week old female Balb/c mice (Mus musculus) from
Charles River Laboratories (CRL) were allowed to accli-
mate for at least 10 days prior to onset of vaccination
studies. Lightly anesthetized animals (isoflurane inhalant)were immunized either intramuscularly (I.M.) (0.5 μg/
100 μl volume of PBS) or intranasally (I.N.) (3 μg/10 μl
volume of PBS into the nostrils) with inactivated
double gradient purified control WIV (A/PR/8/34), CYT-
IVAC~mIL12 and CYT-IVAC~mIL23 (n = 5 mice/group). PBS
administered intramuscularly (I.M.) served as mock (n = 5
mice/group). On day 21, all mice were administered I.M. a
booster dose (I.M. group, 100 ng and I.N. group, 500 ng
total viral protein) of vaccine. Blood was collected from
the retro-orbital sinus on day 19 and day 35 post-
vaccination. Lightly anesthetized animals were challenged
intranasally on day 36 post-vaccination with 100 mouse
lethal dose 50 (MLD50: 50 μl volume) of mouse-adapted
influenza A/PR/8/34 virus. Body weights and clinical
symptoms were monitored daily. All animals were sacri-
ficed at day 4 post-challenge to determine viral lung
loads. Sera, lungs, and nasal washes were collected
post-mortem for biological assays. Quantitative levels of
influenza-specific total IgG and IgA antibodies in serum
or nasal washes were determined by enzyme-linked im-
munosorbent assay, ELISA [15]. For standard curve gener-
ation, anti-mouse IgG (SouthernBiotech) or anti-mouse
IgA (SouthernBiotech) antibodies were serially diluted 2
fold from 160 ng/ml to 0.03125 ng/ml (IgG) or 512 ng/ml
to 0.03125 ng/ml (IgA) respectively. Serum samples were
diluted 1:20 while nasal washes were undiluted for IgA de-
termination. Quantitation of viral loads in frozen lung
samples was determined by tissue culture infectious dose
assay [15].
Results and discussion
Our construct design allows for the expression of murine
IL-12(p35p40) and IL-23(p19p40), both heterodimeric
cytokines, as single chain full-length IL-12p35p40 and
IL-23p19p40 entities joined by a intra-subunit linker
segment fused to the 71 amino acid long membrane an-
choring region (short stalk, transmembrane and cytoplas-
mic tail domain) of the HA gene (HA1513) derived from
influenza A/WSN/33 (H1N1) virus [15] (see Additional
file 1: Figure S1). The latter serves to anchor the hetero-
dimeric cytokine within the plasma membrane and is
recognized by the virus assembly and budding machinery
ensuring packaging within virions. Single chain IL-12 and
IL-23 were chosen as they have been shown to be bio-
active in vitro and in vivo using this constellation [22,23].
Following stable transfection of the virus permissive MDCK
cell line with recombinant plasmids pcDNA3.1-IL-12
(p35p40)/HA1513 and pcDNA3.1-IL-23 (p19p40)/HA1513)
the constitutive cell surface expression of the IL-12 and
IL-23 cytokine fusion proteins were confirmed by im-
munofluorescence microscopy using IL12p40 specific
antibodies (see Additional file 1: Figure S2). MDCK
control cells did not stain positive for surface IL-12
(Additional file 1: Figure S2A) or IL-23 (Additional file 1:
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stable transfectants were infected with influenza virus
(A/PR/8/34) and virions bearing membrane-bound IL-12
(CYT-IVAC~mIL12) and IL-23 (CYT-IVAC~mIL23) were
harvested from the supernatants, gradient-purified and
subsequently inactivated using β-propiolactone (BPL) [15].
Non-adjuvanted whole inactivated virus (A/PR/8/34) WIV
grown from influenza virus infected wild type MDCK cells
was used as control in this study.
Western blot analysis probed with antibodies specific
for IL-12 or IL-23 was employed to validate full-length
incorporation the heterodimeric cytokine fusion con-
structs into the specific CYT-IVAC formulations (Figure 1).
Separation and staining of the CYT-IVAC~mIL12 and
CYT-IVAC~mIL23 formulations respectively (Figure 1A,B)
revealed a prominent band of approximately 70 kDa in
molecular weight. The predicted molecular weights of
membrane-bound IL-12 and IL-23 constructs are 68.93
and 66.87 kDa respectively. The cytokine specific bands
were not detected in our control non-adjuvanted WIV
formulation (PR8). HA incorporation was quantitated
using western blot analysis [15] and quantitation of cy-
tokines (IL-12 and IL-23) was performed (Figure 1C)
using an IL12/IL23p40 specific bead assay as described
by the manufacturer (eBioscience). Together, these data
confirm that our CYT-IVAC formulations display full-
length membrane-bound immunomodulators in direct
context with full-length viral hemagglutinin and other
virion-associated proteins.
To explore in vivo adjuvanticity, female Balb/c mice
were immunized with BPL-inactivated control WIV (A/
PR/8/34), CYT-IVAC~mIL12 and CYT-IVAC~mIL23 (n = 5/
group) either intramuscularly (I.M.) or intranasally (I.N.).
On day 21, all mice were administered a booster dose of
vaccine (I.M.). The I.N. prime followed by the I.M. boost
was employed to mimic priming of mucosal antibody re-
sponses elicited during infection, followed by subsequent
stimulation of systemic immune responses that may onlyFigure 1 Western blot analysis of CYT-IVAC~IL12 and CYT-IVAC~IL23. W
membrane and incubated with IL-12/23p40 antibody followed by anti-spec
CYT-IVAC~IL-12 ranging from 10 μg to 0.5 μg of protein and (B) CYT-IVAC~IL
p40 antibody (eBioscience). (C) Quantitation of virus-incorporated cytokine (pbe marginally elicited by the mucosal route, yet are ac-
tively stimulated following parenteral vaccination. Based
on total viral protein administered, animals received
165 ng/0.33 ng (I.M.) and 1 μg/165 ng (I.N.) of HA pro-
tein respectively during the prime/boost immunizations.
Anti-viral antibody levels elicited by CYT-IVACs and
control non-adjuvanted WIV were determined on both
pre-boost (day 19) and post-boost sera (day 35). As antici-
pated, I.M. immunization induced higher serum antiviral
IgG responses as compared to the mucosal (I.N.) route
supporting previous reports in both animal [24] and hu-
man [25] vaccine studies (Figure 2). Booster vaccination
I.M. was given in all vaccine groups (both I.M. group
and I.N. group) to boost primary responses and led to
significantly higher antiviral IgG levels post-boost
(40 ng/ml to 520 ng/ml) (Figure 2B) compared to pre-
boost levels (25 to 205 ng/ml) within the I.M. group
(Figure 2A). Interestingly, serum IgG antibodies were
detected in the intranasal groups only following parenteral
boosting (5 to 650 ng/ml). The levels were significantly
greater compared to mock (PBS group) (*p < 0.05); albeit
there were no significant differences among vaccinated
groups (Figure 2C).
Further characterization of the antibody isotypes fol-
lowing booster vaccination revealed significantly higher
levels of anti-viral serum IgA in animals that received
CYT-IVAC~mIL12 and CYT-IVAC~mIL23 by the I.N. route
(Figure 3A) compared to control WIV. Interestingly, I.M.
administration of CYT-IVAC~mIL12 also induced signifi-
cantly higher levels of serum anti-viral IgA. Nasal
immunization of soluble cytokines IL-12, IL-1α, IL-18
with an HIV peptide has been shown to induce anti-
HIV peptide serum and mucosal IgA [19]. This is the
first report that membrane-bound IL-12 and IL-23 pre-
sented mucosally also stimulate serum anti-viral IgA.
All immunized animals were challenged on day 36 with
100 LD50 of mouse-adapted influenza virus A/PR/8/34
(H1N1) virus and sacrificed four days later for determininghole viral lysates were run on 12% SDS-PAGE gel, blotted on PVDF
ies secondary antibodies conjugated to HRP. (A) Dilutions of
-23 (lane 2) (5 μg) and PR8 (lane 1) (5 μg) were probed with anti-IL12/23
g of cytokine per μg of vaccine) (FlowCytomix™, eBioscience).
Figure 2 Serum anti-viral IgG antibody responses. 8–10 week old female Balb/c mice (Charles River Laboratories, CRL) were lightly
anesthetized using isoflurane inhalant and immunized with β-propiolactone-inactivated double gradient purified control WIV (A/PR/8/34),
CYT-IVAC~IL-12 and CYT-IVAC~IL-23 (n = 5) either intramuscularly (I.M.) in the right hindquarter or intranasally (I.N.) into the nostrils. PBS administered
I.M. served as the sham-vaccinated group (n = 5). (A) Blood was collected pre-boost on day 19 (B, C), post-boost on day 35 and serum antibody
titers for influenza virus specific IgG were determined by ELISA. Data is displayed as the mean concentration ± SEM. (*p < 0.05 compared to PBS
by One way ANOVA, Bonferroni’s multiple comparison test).
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mucosal antibodies present in the respiratory tract are
known to provide significant protection from influenza in-
fection [26], we collected nasal washes from animals at
day 4 post-infection and determined the anti-viral sIgA
levels as a measurement of the vaccine-induced mucosal
responses; anti-viral sIgA was not detectable in nasal
washes of naïve challenged animals at day 4 (PBS group,
Figure 3B). Both CYT-IVAC~mIL23 and CYT-IVAC~mIL12
vaccinated groups exhibited significantly higher levels of
influenza-specific sIgA (p < 0.001) compared to the controlWIV group, suggesting that both serve as potent mucosal
adjuvants when co-presented in a membrane-bound for-
mulation in direct context with WIV.
Surprisingly, high influenza-specific sIgA levels were
also detected in the nasal washes of animals that received
CYT-IVAC~mIL23 and CYT-IVAC~mIL12 strictly by the I.M.
route (Figure 3B). This is not without precedence, as the
transcutaneous or epicutaneous route of immunization
coupled with mucosal adjuvants including bacterial toxins,
chemical enhancers of cyclic AMP and the active form of
Vitamin D3 have been reported to induce peripheral DC
Figure 3 CYT-IVAC~IL12 and CYT-IVAC~IL23 boost mucosal anti-viral responses. (A) Mice were vaccinated with either non-adjuvanted WIV or
CYT-IVACs. Blood was collected post-boost on day 35 and serum antibody titers for influenza-specific IgA were determined by ELISA. (B) Mice
were challenged with 100LD50 dose of mouse adapted A/PR/8/34 on day 36 following vaccination. At day 4 following challenge, animals (n = 5
mice/group) were sacrificed, nasal washes were collected in PBS (2 ml total volume) and flash frozen. Levels of influenza-specific IgA were
quantitated by ELISA, with IgA standard curve extrapolation. Data represents mean concentration ± SE. (A) IM Group *p < 0.05 compared to WIV;
IN Group *p < 0.05, ***p < 0.001 compared to WIV by One way ANOVA, (B) ***p < 0.001 compared to WIV, One way ANOVA Bonferroni’s multiple
comparison test).
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sequent priming of T and B cells for mucosal homing
[27-29]. Hence, our membrane-anchored IL-12 and IL-23
adjuvants may be activating dendritic cells in muscle tissue
and targeting them to migration in draining lymph nodes,
in a state that is conducive for priming T and B cells for
homing to mucosal tissues.Figure 4 CYT-IVAC immunization reduces viral lung burden following
with a 100LD50 dose of mouse-adapted A/PR/8/34 on day 36 following vac
lung tissues were collected and flash frozen. Viral loads from homogenized
assay. Data is expressed as TCID50 per gram of lung tissue. (*p < 0.05, **p <
multiple comparison test.A reduction in viral titers in lung tissue of vaccinated
animals following viral challenge serves as a valuable
correlate of protective efficacy of viral vaccines [30].
Whereas I.M. vaccination of either CYT-IVAC~mIL23 or
CYT-IVAC~mIL12 was able to reduce viral lung loads at
day 4 post-challenge compared to non-vaccinated con-
trols, they only trended towards a better protectivechallenge. Animals vaccinated I.M. (A) or I.N. (B) were challenged
cination. At day 4 following challenge, animals (n = 5) were sacrificed,
lung tissue (n = 5) were determined by tissue culture infectious dose
0.01, ***p < 0.001 compared to PBS, one way ANOVA, Bonferroni’s
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Interestingly, we found that recall IgA levels in nasal
washes were significantly higher in both CYT-IVAC
groups than the WIV non-adjuvanted group following
lethal challenge irrespective of the route of administra-
tion. These responses may be responsible for some of
the variation of viral lung loads observed in animals re-
ceiving CYT-IVACs by the IM route. However, this also
suggests that there are fundamental differences in the
specificity of mucosal induced anti-viral IgA compared
to anti-viral IgA responses induced at other parenteral
sites.
Mucosal administration of CYT-IVAC~mIL23 or CYT-
IVAC~mIL12 led to significantly reduced viral loads upon
challenge compared to the non-adjuvanted WIV control
group (Figure 4B); these data correlated well with the
observed high levels of sIgA detected in serum and the
nasal wash of these animals. This is the first time that the
membrane-bound IL-12 or IL-23 co-presented directly on
influenza WIV has been found to induce robust mucosal
immune responses. Soluble IL-12 as a nasal adjuvant is
well documented [6] and has been reported to stimulate
mucosal sIgA and systemic IgG antibody as well as cellular
responses in a variety of vaccine formulations [8]. Our
data supports these observations, but also suggest that
even low concentrations of IL-12 (picograms) can be used
in a membrane-bound formulation to boost mucosal sIgA
levels. IL-23 inducing mucosal antibody responses is a
novel observation and clearly further work is required
to address the mechanism. Based on previous reports of
IL-17 influencing B cell activation [31] and germinal
center development [32], the IL-23 bearing CYT-IVAC
could be modulating Th17 responses. Recently, activation
of lung Th17 cells were also found to induce the devel-
opment of polymeric Ig receptor and elevate mucosal
secretion of IgA antibodies [33]. Besides IgA antibodies,
anti-viral IgG in BAL fluids as well as T cell responses
all contribute towards protection and recovery from
viral challenge.
Our approach of using cytokines in direct context
with WIV vaccines involves very low amounts of cytokine
(picograms per microgram of vaccine). This approach may
potentially lower the amount of antigen required to induce
protection and may also lower the incidence of adverse
side effects reported for WIVs. In most studies soluble
cytokines have been administered in μg amounts, which
is clearly well in excess of the amounts utilized in the
present study; albeit the total number of doses and dos-
ing schedules vary significantly depending on the study
(reviewed extensively in [8,10]. It should be noted that
soluble IL-23 has been reported to have adverse effects
such as inducing chronic inflammation and autoimmune
disease [34,35] and both antitumor and tumor promot-
ing effects [36,37]. Our approach that limits systemicdistribution of cytokines may overcome some of the safety
issues and potential autoimmune inflammatory reactions
from soluble IL-23.
In summary, this is the first report of the nasal adjuvan-
ticity of both IL-12 and IL-23 in a membrane-bound for-
mulation co-presented with WIV. In light of our recent
study using our CYT-IVAC approach in “aged” mice, we
hypothesize that both the IL-12 and IL-23 expressing
CYT-IVAC formulations may show even more promise as
a mucosal formulation for the elderly, but this will require
further more in depth investigation. Finally, this study
revisits the use of WIV vaccine formulations adjuvanted
for mucosal delivery. Future experiments focusing on
evaluating protective efficacy of dose sparing with muco-
sally administered CYT-IVAC~IL-12 and CYT-IVAC~IL-23
vaccines in both young and old preclinical challenge
models are needed to provide greater insights on the
efficacy of these vaccines.
Additional file
Additional file 1: Figure S1. Pictorial diagram of CYT-IVAC gene
constructs. (A) CYT-IVACIL-12fusion gene construct (1620 bp) was
composed of mIL-12p35p40 subunits joined by short hydrophobic linker
molecule(Li) fused in frame to the a short 222 bp coding region of the
Hemagglutinin (HA) gene derived from Influenza virus (A/WSN/33), which
encodes for a short extracellular stalk region and the transmembrane and
cytoplasmic tail region of the HA (HA1513). (B) The CYT-IVACIL-23 fusion
gene construct was constructed in a similar fashion. Both cytokine genes
were subcloned into the pcDNA3.1 expression vector, placed under control
of the CMV promoter (pCMV). Figure S2. Indirect immunofluorescence cell
surface staining of MDCK transfectant cell lines cell lines constitutively
expressing mIL-12/HA (C) and mIL-23/HA (D) with MDCK cells serving as
negative control (A,B) using cytokine specific antibodies.
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